Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study
Alimentary Pharmacology & Therapeutics2020Vol. 52(8), pp. 1366–1376
Citations Over TimeTop 10% of 2020 papers
V Asscher, Vince Biemans, Marieke Pierik, Gerard Dijkstra, Mark Löwenberg, Sander van der Marel, Nanne K.H. de Boer, Alexander Bodelier, Jeroen M. Jansen, Rachel West, J Haans, Willemijn A. van Dop, Rinse K. Weersma, Frank Hoentjen, Jeroen Maljaars, the Dutch Initiative on Crohn and Colitis (ICC)
Abstract
Comorbidity - but not age - is associated with an increased risk of hospitalisations on either treatment, and with any infection on vedolizumab. This underlines the importance of comorbidity assessment and safety monitoring of IBD patients.
Related Papers
- → Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease(2018)129 cited
- → Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study(2022)11 cited
- → Letter: potential selection bias in the real‐world comparison of ustekinumab versus vedolizumab as a second‐line treatment for Crohn’s disease(2022)1 cited
- → P386 Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumab(2021)
- → P688 Comparative Effectiveness of Ustekinumab Versus Vedolizumab in Treating Crohn’s Disease After Failure of Anti-TNF Agents: Real-World Evidence(2024)